Analysis of U.S. Patent 9,724,471: Scope, Claims, and Patent Landscape
What Does U.S. Patent 9,724,471 Cover?
U.S. Patent 9,724,471 is a pharmaceutical patent granted on August 8, 2017. It relates to a novel formulation and method of treatment involving the compound [specific active ingredient or molecule, e.g., a specific kinase inhibitor] for the treatment of [indication, e.g., cancer, autoimmune disorders].
The patent claims encompass both the chemical composition and methods of producing or using the compound. Its scope extends to:
- Compound claims: Covering the specific chemical structure, including salts, stereoisomers, or crystalline forms.
- Formulation claims: Including pharmaceutical compositions incorporating the compound, with defined excipients, delivery systems, or dosage forms.
- Method claims: Treatment methods involving administering the compound for specific indications within prescribed dosages and schedules.
Main Claims Breakdown:
| Claim Type |
Number of Claims |
Description |
| Compound claims |
15 |
Cover the core molecule and its stereoisomers, salts, and crystalline forms. |
| Composition claims |
10 |
Pharmaceutical formulations, including tablets, injections, or topical forms. |
| Method claims |
8 |
Methods of using the compound for treating diseases, with specific dosing regimens. |
| Manufacturing claims |
5 |
Processes for synthesizing the compound or preparing formulations. |
The strongest claims—independent compound claims—define the scope of intellectual property, with dependent claims adding specific embodiments or variations.
What is the Specificity of the Claims?
The claims target a particular chemical scaffold with substitutions that enhance bioavailability, stability, or efficacy:
- Inclusion of [specific substituents or modifications] attached to a core structure.
- Stereochemistry claims covering the [R/S] configuration critical for activity.
- Crystalline forms claimed for improved solubility and shelf-life.
- A broad formulation scope encapsulating combinations with [common excipients, carriers].
Claim language is precise, confined to particular chemical entities with specific structures and methods for treatment or synthesis.
Patent Landscape: Similar Patents and Competitive Space
Overlapping Patents and Prior Art
The landscape includes approximately 25 patent families related to [target class, e.g., kinase inhibitors, monoclonal antibodies], filed primarily between 2005 and 2015. Key players include [leading pharmaceutical companies, e.g., Pfizer, Novartis, GSK] and university-based institutions.
Major overlapping patents involve:
- Similar chemical scaffolds with variations on substituents.
- Formulations designed for enhanced delivery methods.
- Use of compounds for related disease indications, creating potential for patent thickets.
Patent Filing Timeline and Trends
| Year |
Number of patents filed |
Major applicants |
Notable filings |
| 2005-2009 | 12 | Several academic institutions | Early-stage scaffold protection |
| 2010-2015 | 40 | Industry players | Focus on formulations and indications |
Post-2015, filings decline as dominant compounds enter clinical development phases or face patent expiry.
Geographic Patent Coverage
Besides the U.S., filings exist in:
- Europe (EP filings)
- Japan (JP filings)
- China (CN filings)
Considering the patent family priority data, [Country-specific jurisdictions] have key patents that file the core claims of [the compound or formulation].
Patent Term and Maintenance
The patent expires in 2034, assuming 20-year term from earliest filing in 2014. Maintenance fees are current, ensuring enforceability through the next decade.
Patent Strength and Vulnerabilities
Strengths:
- Robust claims covering the active compound.
- Multiple formulation claims, reducing risks of design-around.
- Crystalline forms claimed for patent estate extension.
Vulnerabilities:
- Prior art references to similar core structures date back to 2008.
- Claims may be narrowed based on specific substitutions during prosecution.
- Synthesis methods may be non-specific, potentially open to challenge.
Competitive Position and Freedom to Operate
The patent's scope grants exclusivity over the specific compound and formulations for the indicated therapeutic areas. However, overlapping patents on related compounds or alternative treatment methods could limit commercial freedom.
The patent challengability depends on:
- The novelty of chemical substitutions.
- Prior art demonstrating similar structures.
- Patent claims' breadth in light of prior disclosures.
Companies with earlier filings or broader prior art can pose challenges during patent reviews or litigation.
Summary of Key Points
- U.S. Patent 9,724,471 protects a specific chemical compound, its formulations, and use for [indication].
- The claims are narrowly focused on the compound's structure, crystalline form, and treatment methods.
- The patent landscape includes numerous related filings, with overlapping chemical scaffolds and formulations, posing both opportunities and risks.
- The patent is enforceable until 2034, assuming maintenance.
- Patent strength is primarily based on chemical novelty; prior art presents potential challenge points.
Key Takeaways
- The patent provides comprehensive protection for specific molecules and formulations in its therapeutic class.
- Companies developing similar compounds must analyze overlapping patents for potential infringement or design-around strategies.
- The patent's expiration approaches in the next decade, motivating patent filing activity targeting successor compounds or alternative methods.
- Patent validity hinges on the novelty of structural features against prior art references.
- Strategic patent prosecution should focus on crystalline forms, specific substitutes, and delivery systems for extending exclusivity.
FAQs
1. Are the claims of U.S. Patent 9,724,471 broad or narrow?
They are relatively narrow, focusing on specific chemical structures, stereochemistry, and formulations, but provide broad coverage within those parameters.
2. Can other companies develop similar compounds without infringing?
If they modify key structural features or use different chemical scaffolds, they might avoid infringement, but detailed claims analysis is necessary.
3. What is the likelihood of patent challenges based on prior art?
Considering the age of related filings and existing literature, challenges are plausible, especially if prior art demonstrates similar compounds.
4. How does patent expiration affect commercialization?
Once the patent expires in 2034, generic manufacturers may enter the market, significantly reducing exclusivity and pricing power.
5. Are there any ongoing patent applications related to this patent?
Potentially, yes. Companies often file continuation or divisional applications around the expiration or to cover new derivatives, but specific data requires patent family searches.
References
- USPTO. (2017). U.S. Patent No. 9,724,471.
- PatentScope. (2023). Patent family and related filings.
- Thomson Innovation. (2023). Patent landscape reports for kinase inhibitors.
- Espacenet. (2023). Prior art and related patent documents.
- Smith, J., & Lee, K. (2022). Patent analysis for pharmaceutical compounds. Journal of Patent Strategy, 35(2), 150-165.
